Selank

No. Selank is not an FDA-approved drug, and it has not been evaluated by the FDA for the diagnosis, treatment, cure, or prevention of any disease. We treat it as investigational and use it as part of an individualized wellness plan. Most of the published clinical work comes out of Russia, where it has been studied as an anxiolytic with comparisons to the benzodiazepine medazepam. Much of the rest is preclinical, and Western trial data is thin. We say that out loud rather than burying it. The peptide we use is sourced from specialty peptide distributors that run Certificate of Analysis testing on every lot for identity, purity, and concentration. It is prescribed and supervised by Dr. Oliver Morris, Medical Director. It is not a substitute for established care of a diagnosed anxiety disorder.

Not in how it behaves, though there is a mechanistic overlap worth understanding. Selank appears to act as a positive modulator at GABA-A receptors and to influence enkephalin signaling, so it touches some of the same machinery. What is different is the pattern. In the published comparative work, Selank has not been associated with the sedation, dependence, or withdrawal seen with benzodiazepines. Patients generally describe a calmer baseline without feeling slowed down. That said, the GABAergic activity raises a theoretical question about additive effects, which is why we are cautious in patients who use benzodiazepines, gabapentinoids, or alcohol regularly. Selank also is not a replacement for monitored pharmacotherapy in a diagnosed anxiety disorder. It is a short-course tool for a defined stressful window, not a swap for established treatment.

Days, not hours. Most patients describe a quieter baseline within three to seven days of starting, rather than a noticeable effect from a single dose. If you are expecting something that hits within twenty minutes, this is the wrong tool, and we would tell you that during the consultation. Along with the calmer baseline, patients report better focus through the day without sedation, improved sleep quality during the cycle, and less rumination or racing thought. Response is individual and we don't guarantee outcomes. Because the effect builds over days, the protocol is structured as a short course rather than an as-needed dose. Timing matters for the same reason. If you know a difficult stretch is coming, starting before it lands makes more sense than starting in the middle of it.

Short cycles, typically one to two weeks on, with breaks between courses. Most of the published clinical work uses five to fourteen day courses, often with breaks before re-dosing, and we follow that pattern. Dosing is once daily by subcutaneous injection into the abdomen, with the dose determined by your provider rather than set by a chart. Selank is meant for a defined window: a difficult run at work, travel, a transition, a high-stress family stretch. It is not a daily background medication, and we don't run it continuously. Patients who do best treat it as a tool for a specific period and have already addressed sleep, caffeine, alcohol, and other obvious drivers. If a course isn't doing what you hoped, the answer is to revisit it, not to keep extending.

Fair question, and the honest answer is that they are not the same route. Most published clinical work on Selank is intranasal. We use the injectable subcutaneous form in this practice, dosed into the abdomen. That is a real gap between the literature and what is in front of you, and it is one of the reasons we run short courses and stay conservative about who is a candidate. It is also part of why we frame Selank as investigational rather than proven. During the consultation we go through what the evidence actually supports and where it runs out, so you can decide with the real picture in hand. If that uncertainty doesn't sit well with you, that is a completely reasonable place to land.

It depends on what you are taking, and this is exactly what the intake is for. We are cautious in patients on benzodiazepines or gabapentinoids, or who use alcohol regularly, because Selank's GABAergic activity raises a theoretical question about additive effects. There is not good data telling us how those combinations behave in real people, so we err toward caution rather than assumption. Selank is also avoided in pregnancy and breastfeeding, where there is no safety data. And it is not a substitute for established care of a diagnosed anxiety disorder that benefits from monitored pharmacotherapy. If you are already in treatment for anxiety, the right move is a conversation that includes the provider managing that care, not quietly adding something on top of it.